STOCK TITAN

Si-Bone - SIBN STOCK NEWS

Welcome to our dedicated page for Si-Bone news (Ticker: SIBN), a resource for investors and traders seeking the latest updates and insights on Si-Bone stock.

Company Overview

Si-Bone Inc. is a specialized medical device company with a focused mission to improve patient outcomes in the realm of orthopedic surgery, particularly in the treatment of sacroiliac joint dysfunction. As a pioneer in the field, Si-Bone has developed a proprietary, minimally invasive implant system aimed at facilitating sacroiliac joint fusion. Leveraging patents for titanium implant technologies, the company has made significant strides in reducing the invasiveness of traditional sacroiliac joint fusion procedures.

Core Business and Innovation

At the heart of its operations, Si-Bone’s innovative approach is encapsulated in its iFuse Implant System, which is designed to provide a reliable alternative to conventional surgical techniques. The company has successfully combined advanced engineering with practical surgical approaches to produce a system that addresses complex conditions such as sacroiliac joint dysfunction, degenerative sacroiliitis, and pelvic trauma. The product portfolio includes instruments and implantable bone products that facilitate the fusion process during minimally invasive procedures, creating a distinct market niche with several industry-specific keywords such as minimally invasive surgery, orthopedic implants, and joint fusion.

Technological Advancements

Si-Bone separates itself from competitors through its commitment to technological innovation. The iFuse Implant System, along with its variations such as iFuse-TORQ and iFuse Bedrock Granite, incorporates breakthrough design and engineering principles to ensure safety and efficacy within complex anatomical regions. These devices are supported by rigorous clinical research and designed to provide enhanced pelvic fixation, particularly during concurrent lumbar spinal fusion procedures. This focus on precision technology underscores the company’s strategic positioning within the medical device market.

Clinical and Surgical Impact

The clinical implications of Si-Bone’s technology are noteworthy, especially for patients who have traditionally faced limited treatment options in the context of sacroiliac joint dysfunction. The minimally invasive nature of the iFuse Implant System offers advantages such as reduced recovery times, fewer complications compared to traditional open surgery, and a more targeted approach in addressing structural conditions. By improving the procedural experience for both patients and surgeons, Si-Bone plays a critical role in evolving standards of care in orthopedic surgery.

Market Position and Competitive Landscape

Si-Bone operates within a highly specialized sector of the medical device industry, marked by its focus on orthopedic applications. The company’s targeted approach to sacroiliac fusion procedures and its suite of patented implant products have carved a niche in an industry characterized by continuous innovation and rigorous safety standards. While there are other players in the broader field of orthopedic devices, Si-Bone differentiates itself by addressing the challenges associated with under-diagnosed and under-treated sacroiliac joint conditions using less invasive methods. The company’s seasoned management team, with experience from major industry names, further reinforces its authority and capability in driving orthopedic innovation.

Operational Excellence and Quality Assurance

Operating under stringent regulatory frameworks, Si-Bone emphasizes both the safety and effectiveness of its implant systems. The company’s operational strategy combines deep clinical expertise with advanced technological design, ensuring each product meets high standards of quality and efficacy. By integrating comprehensive research and development with real-world surgical feedback, Si-Bone is able to continuously refine its products, aiming to maintain robust patient safety profiles and reliable clinical outcomes.

Expertise and Industry Recognition

Si-Bone’s standing in the orthopedic device community is bolstered by its innovative approaches and the robust clinical data supporting its technologies. The company’s adoption of breakthrough design methods and its ability to translate complex medical needs into effective surgical solutions showcase its technical expertise. For healthcare professionals, patients, and stakeholders, Si-Bone represents a blend of advanced engineering, clinical precision, and a commitment to minimally invasive treatment paradigms, making it a respected name within its competitive landscape.

Comprehensive Product Portfolio

The diverse portfolio from Si-Bone is characterized by a range of implant systems designed to address various orthopedic conditions. It includes systems that directly target sacroiliac joint fusion as well as those that serve broader applications such as adjacent spinal conditions and pelvic trauma. This diversified approach allows clinicians to select devices tailored to the specific needs of their patients while maintaining consistency in surgical outcomes.

Conclusion

In summary, Si-Bone Inc. is an innovator in the orthopedic medical device space, focused on developing minimally invasive, patented implant systems for sacroiliac joint fusion and related applications. Through its continuous commitment to research, quality assurance, and operational precision, the company has established a strong market presence and a clear value proposition within a niche yet critically important segment of orthopedics. Its pioneering technologies, underscored by substantial clinical validation and a robust product portfolio, position it as an informative case study for anyone seeking a deep understanding of advanced orthopedic solutions.

Rhea-AI Summary

SI-BONE, Inc. (Nasdaq:SIBN) announced preliminary unaudited revenue for Q3 and the first nine months of 2020. Q3 revenue is anticipated between $20.1-$20.4 million, marking a 24%-26% increase year-over-year. U.S. revenue is estimated at $18.7-$18.9 million with a 26%-27% growth. For the nine months, revenue is expected between $51.0-$51.3 million, an 8%-10% increase from 2019. Despite this growth, SI-BONE expresses caution due to the ongoing impacts of COVID-19. Third-quarter results will be disclosed on November 2, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none
-
Rhea-AI Summary

SI-BONE, a medical device company, announced a virtual surgeon panel led by CEO Jeffrey Dunn on October 8, 2020, from 10am to 11am ET. The panel will feature renowned experts discussing the treatment of sacroiliac joint dysfunction and the role of telehealth in surgery.

Panelists include Dr. Peter Whang from Yale, Dr. Bharat Desai from Panorama Orthopedics, Dr. William Tobler from Mayfield Clinic, and Dr. Robert Eastlack from Scripps Health. Interested attendees can register through SI-BONE’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
conferences
-
Rhea-AI Summary

SI-BONE, a leader in medical devices for musculoskeletal disorders, announced its participation in the upcoming Morgan Stanley 18th Annual Global Healthcare Conference and 2020 Cantor Global Healthcare Conference. Management will present at a Fireside Chat on September 15, 2020, at 5:00 p.m. ET and September 16, 2020, at 12:20 p.m. ET. Interested parties can access the live and archived webcasts on the company's website. The company is known for its iFuse Implant System, designed for minimally invasive SI joint fusion, supported by extensive clinical studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq:SIBN) reported Q2 2020 financial results, with revenue of $14.0 million, a 14% decrease year-over-year. U.S. revenue totaled $13.2 million, down 12%. International revenue fell by 36% to $0.8 million, largely due to COVID-19's impact on surgical volumes. The company completed a $40 million debt refinancing and received positive coverage from Aetna, covering over 22 million members. The gross margin decreased to 85% from 90%, and the net loss widened to $12.5 million or $0.44 per diluted share. Guidance for 2020 remains withdrawn amid ongoing uncertainty.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.16%
Tags
-
Rhea-AI Summary

SI-BONE, a medical device company focused on sacropelvic disorders, announced its participation in the 40th Annual Canaccord Genuity Growth Conference. The company will conduct a live Fireside Chat on August 12, 2020, at 1:00 p.m. ET. Interested individuals can access the webcast via the company's website. SI-BONE's iFuse Implant System, designed for minimally invasive sacroiliac joint fusion, is supported by multiple clinical studies demonstrating its effectiveness in treating chronic low back pain. The device has been commercially available since 2009 and is covered by various insurance payors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
conferences
-
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN) will announce its Q2 2020 financial results post-market on August 3, 2020. The management team will host a conference call at 1:30 PM PT, accessible via the company’s website. SI-BONE specializes in minimally invasive surgical solutions for sacropelvic disorders, notably through its iFuse Implant System, which addresses chronic low back pain. Supported by numerous clinical studies, the iFuse Implant is the only SI joint fusion device with established insurance coverage for the procedure. Detailed company and product information can be found on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences earnings
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company in California, has successfully re-financed its existing $40 million credit facility. The new five-year term loan, secured through Solar Capital Partners, features an interest rate of 9.40% plus the greater of the 1-month LIBOR Rate or 0.33%. This strategic move will enhance SI-BONE's balance sheet and provide improved operating flexibility. The new loan includes a 36-month interest-only period followed by 24 months of amortization. The refinancing indicates the company's strong operational performance and dedicated team.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.55%
Tags
none
-
Rhea-AI Summary

SI-BONE, Inc. announces that Aetna has established a positive coverage policy for the iFuse Implant System to treat sacroiliac joint dysfunction. Effective May 28, 2020, this policy grants over 22 million Aetna members access to the minimally invasive SI joint fusion when deemed medically necessary. This decision is supported by extensive clinical evidence, including 5-year results from a prospective study. SI-BONE highlights that the iFuse procedure is crucial for patients suffering from SI joint pain, enhancing accessibility and treatment adoption.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
-
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company, will participate in the Bank of America Securities 2020 Health Care Conference on May 13, 2020. The management team will conduct a live Fireside Chat at 8:40 a.m. PT / 11:40 a.m. ET, accessible via the company's website. SI-BONE specializes in minimally invasive surgery for sacroiliac joint disorders with its iFuse Implant System, which has shown significant clinical benefits in treating chronic low back pain. The company emphasizes the importance of their research-backed device in enhancing patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
conferences
Rhea-AI Summary

SI-BONE, Inc. (Nasdaq:SIBN) reported Q1 2020 revenue of $16.8 million, marking a 12% increase year-over-year. U.S. revenue reached $15.3 million, a 14% rise, despite lower case volumes in late March due to COVID-19. Gross margin stood at 89%, down from 90% in 2019, while operating expenses rose 20% to $26.8 million. The net loss was $12.8 million, or $0.47 per diluted share, compared to $9.3 million in the same period last year. The company has withdrawn its 2020 guidance due to COVID-19 uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.68%
Tags

FAQ

What is the current stock price of Si-Bone (SIBN)?

The current stock price of Si-Bone (SIBN) is $13.63 as of April 22, 2025.

What is the market cap of Si-Bone (SIBN)?

The market cap of Si-Bone (SIBN) is approximately 554.0M.

What is the primary focus of Si-Bone?

Si-Bone specializes in developing and commercializing innovative, minimally invasive implant systems designed for sacroiliac joint fusion, addressing complex orthopedic conditions.

How does the iFuse Implant System benefit patients?

The iFuse Implant System offers a less invasive alternative to traditional sacroiliac joint fusion surgery, resulting in reduced recovery times and potentially fewer complications.

What types of conditions does Si-Bone target with its products?

Si-Bone addresses conditions such as sacroiliac joint dysfunction, degenerative sacroiliitis, pelvic trauma, and specific challenges associated with spinal deformity.

How does Si-Bone differentiate itself in the orthopedic device industry?

Si-Bone differentiates itself by focusing on a niche market with its patented, minimally invasive technologies and by leveraging a management team with deep industry expertise from leading orthopedic companies.

What are the key benefits of minimally invasive surgical systems?

Minimally invasive systems typically provide improved patient recovery experiences, reduced overall surgical trauma, and enhanced precision during implant procedures, which are all hallmarks of Si-Bone's approach.

How does Si-Bone ensure the quality and safety of its products?

Si-Bone integrates rigorous clinical research and strict quality assurance protocols into its design and manufacturing process, ensuring that its implant systems meet high standards of safety and efficacy.
Si-Bone

Nasdaq:SIBN

SIBN Rankings

SIBN Stock Data

554.01M
37.46M
3.09%
95.51%
2.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA